← Russell 3000 cross-section

LFMD LifeMD, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-05, not restated
Healthcare

Scale

Market cap
$158m
Revenue TTM
$164m
Net income TTM
$-1m
Free cash flow
$-11m
Composite score
Sector rank
#2946

Valuation

P / E
EV / EBITDA
EV / sales
1.0
FCF yield
-6.99%
Earnings yield vs 10-yr
-5.30pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-0.6%
EBITDA margin
-15.1%
ROE
-11.4%
ROIC
-318.4%
Revenue growth
-33.4%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Results of Operations During the three months ended September 30, 2025, the Company identified and corrected errors related to the recording of net revenue as agent in certain arrangements with the Company’s third-party pharmacy providers as well as various out-of-period amounts included in our previously issued financial statements that were deemed to be quantitatively and qualitatively immaterial, individually and in the aggregate, to the financial statements in the periods recorded or to the relevant prior periods. …LifeMD, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-05

Read the full passage →